

---

## **6 Literaturverzeichnis**

---

Aarons RD, Nies AS, Gal J, Hegstrand LR, Molinoff PB:  
Elevation of  $\beta$ -adrenergic receptor density in human lymphocytes  
after propranolol administration.  
J Clin Invest 65:949-957, 1980.

Aarons RD, Molinoff PB:  
Changes in the density of beta adrenergic receptors in rat  
lymphocytes, heart and lung after chronic treatment with  
propranolol.  
J Pharmacol Exp Ther 221: 439-443, 1982.

Ahlquist RP:  
A study of the adrenotropic receptors.  
Am J Physiol 153:586-600, 1948.

Alexander RW, Cooper B, Handin RI:  
Characterization of the human platelet  $\alpha$ -adrenergic receptor.  
J Clin Invest 62:1136-1144, 1978.

Alexander RJ, Fenton JW, Detwiler TC:  
Thrombin-platelet interactions: an assessment of the roles of  
saturable and nonsaturable binding in platelet activation.  
Arch Biochem Biophys 222:266-275, 1983.

Amann FW, Bolli P, Kiowski W, Bühler FR:  
Enhanced alpha-adrenoceptor-mediated vasoconstriction in  
essential hypertension.  
Hypertension 3 [Suppl I]:I-119 - I-123, 1981.

Arai S, Hori S, Aramori I, Ohkubo H, Nakanishi S:  
Cloning and expression of a cDNA encoding an endothelin  
receptor.  
Nature (Lond) 348:730-2, 1990.

Ashida T, Tanaka T, Yokouchi M, Kuramochi M, Deguchi F, Kimura G,  
Kojima G, Ito K, Ikeda M:  
Effekt of dietary sodium on platelet  $\alpha_2$ -adrenergic receptors in  
essential hypertension.  
Hypertension 7:972-978, 1985.

Atweh SF, Kuhar MJ:  
Autoradiographic localization of opiate receptors in the rat  
brain. II. The brain stem.  
Brain Res 129:1-12, 1977.

Banks WA, Kastin AH:  
Saturable transport of peptides across the blood-brain barrier.  
Life Sci 41:1319-1338, 1987.

Berettini WH, Post RM, Worthington EK, Casper JB:  
Human platelet vasopressin receptors.  
Life Sci 30:425-432, 1981.

Berridge MJ:  
Inositol triphosphate and diacylglycerol as second messengers.  
Biochem J 220:345-360, 1984.

Berridge MJ, Irvine RF:  
Inositol triphosphate, a novel second messenger in cellular  
signal transduction.  
Nature (London) 312:315-321, 1984.

Berthelsen S, Pettinger WA:  
A functional basis for classification of alpha-adrenergic  
receptors.  
Life Sci 21:595, 1977.

Bianchetti MG, Weidmann P, Beretta-Piccoli C, Rupp U, Boehringer  
K, Link L, Ferrier C:  
Disturbed noradrenergic blood pressure control in normotensive  
members of hypertensive families.  
Br Heart J 51:306-311, 1984.

Birnbaumer L, Codina J, Mattera R, Cerione RA, Hildebrandt JD,  
Sunyer T, Rojas FJ, Caron MG, Lefkowitz RJ, Iyengar R:  
Structural basis of adenylate cyclase stimulation and inhibition  
by distinct guanine nucleotide regulatory proteins.  
In: Cohen P, Houslay MD (eds) Molecular aspects of cellular  
regulation, Vol 4: Molecular mechanisms of transmembrane  
signalling Elsevier, Amsterdam, pp 131-182, 1985.

Blaustein MP:  
Sodium ions, calcium ions, blood pressure regulation, and  
hypertension: a reassessment and a hypothesis.  
Am J Physiol 232:C165-173, 1977.

Blaustein MP, Ashida T, Hamlyn JM:  
Sodium metabolism and hypertension: how are they linked?  
Klin Wochenschr 65 [Suppl VIII]:21:32, 1987.

Bohr DF:  
Adrenergic receptors in coronary arteries.  
Ann NY Acad Sci 139:799, 1967.

Bolli P, Erne P, Kiowski W, Ji BH, Amman FW, Bühler FR:  
Important contribution of post-junctional alpha<sub>2</sub>-adrenoceptor  
mediated vasoconstriction in man.  
J Hypertens 1:257-259, 1983.

Bolli P, Erne P, Kiowski W, Amman FW, Bühler FR:  
The adrenaline alpha<sub>2</sub>-adrenoceptor-mediated vasoconstrictor  
axis.  
Clin Sci 68 [Suppl 10] 141s, 1985.

Bolli P, Erne P, Block LH, Ji BH, Kiowski W, Bühler FR:  
Adrenaline induces vasoconstriction through postjunctional  
α<sub>2</sub>-adrenoceptor stimulation which is enhanced in essential  
hypertension.  
J Hypertens 2 [Suppl 3]: S115-S118, 1984.

Boon NA, Elliot JM, Davies CL, Conway FJ, Grahame-Smith DG,  
Sleight P:  
Platelet α-adrenoceptors in borderline and established essential  
hypertension.  
Clin Sci 65:297-298, 1983.

Bouloux PMG, Grossman A, Al-Damluji S, Bailey T, Besser GM:  
Enhancement of the sympathoadrenal response to the cold-pressor  
test by naloxone in man.  
Clin Sci 69:365-368, 1986.

Bradley AB, Morgan KG:  
Cellular Ca<sup>2+</sup> monitored by aequorin in adenosin-mediated smooth  
muscle relaxation.  
Am J Physiol 248:H109-117, 1985.

Bramnert M, Hökfelt B:  
Lack of effect of naloxone in a moderate dosage on the exercise-  
induced increase in blood pressure, heart rate, plasma  
catecholamines, plasma renin activity and plasma aldosterone in  
healthy males.  
Clin Sci 68:185-191, 1985.

Brass LF:  
Ca<sup>2+</sup> homeostasis in unstimulated platelets.  
J Biol Chem 259:12563-12570, 1984.

Breddin HK, Ziemann M, Bauer O, Harmann W, Schaudinn L,  
Schlosser U, Winterhagen A, Krzywanek HJH:  
Time and temperature dependent change of ADP and collagen  
induced and spontaneous aggregation.  
Thromb Res 19:621-638, 1980.

Brodde O-E, Engel G, Hoyer D, Bock KD, Weber F:  
The  $\beta$ -adrenergic receptor in human lymphocytes:  
classification by the use of a new radioligand,  
 $(\pm)$ - $^{125}$ Iodocyanopindolol.  
Life Sci 29:2189-2198, 1981.

Brodde O-E, Hardung A, Ebel H, Bock KD:  
GTP regulates binding of agonists to  $\alpha_2$ -adrenergic receptors in  
human platelets.  
Arch Int Pharmacol-dyn Ther 258:193-207, 1982.

Brodde O-E, Prywarra A, Daul A, Anlauf M, Bock KD:  
Correlation between lymphocyte  $\beta_2$ -adrenoceptor density and mean  
arterial blood pressure: elevated  $\beta$ -adrenoceptors in essential  
hypertension.  
J Cardiovasc Pharmacol 6:678-682, 1984.

Brodde O-E, Stuka N, Demuth V, Fresel R, Bergerhausen J, Daul A,  
Bock KD:  
Alpha- and beta-adrenoceptors in circulating blood cells of  
essential hypertensive patients: increased receptor density and  
responsiveness.  
Clin Exp Hypertens A7:1135-1150, 1985a.

Brodde O-E, Daul A, Stuka N, O'Hara N, Borchard U:  
Effects of  $\beta$ -adrenoceptor antagonist administration on  
 $\beta_2$ -adrenoceptor density in human lymphocytes. The role of the  
"intrinsic sympathomimetic activity".  
Naunyn-Schmiedeberg's Arch Pharmacol 328:417-422, 1985b.

Brodde O-E, Schemuth R, Brinkmann M, Wang XL, Daul A,  
Borchard U:  
 $\beta$ -Adrenoceptor antagonists (non-selective as well as  
 $\beta_1$ -selective) with partial agonistic activity decrease  
 $\beta_2$ -adrenoceptor density in human lymphocytes. Evidence for a  
 $\beta_2$ -agonistic activity.  
Naunyn-Schmiedeberg's Arch Pharmacol 333:130-138, 1986.

Brodde O-E:  
Cardiac beta-adrenergic receptors.  
ISI Atlas of science: Pharmacology 1:107-112, 1987.

Brodde O-E, Michel MC, Beckeringh JJ:  
Alterations of  $\beta$ -adrenoceptor function in essential  
hypertension.  
J Cardiovasc Pharmacol 10 [Suppl 4]:S50-S54, 1987.

Brodde O-E, Seher U, Nohlen M, Fischer WM, Michel MC:  
Correlation between human myometrial and platelet  
alpha<sub>2</sub>-adrenoceptors.  
Europ J Pharmacol 150:403-404, 1988.

Bruschi G, Bruschi MW, Caroppo M, Orlandini G, Pavarani C,  
Cavatorta A:  
Intracellular free Ca<sup>2+</sup> in circulating lymphocytes of  
spontaneously hypertensive rats.  
Life Sci 35:535-542, 1984.

Bruschi G, Bruschi MW, Caroppo M, Orlandini G, Spaggiari M,  
Cavatorta A:  
Cytoplasmatic free [Ca<sup>2+</sup>] is increased in the platelets of  
spontaneously hypertensive rats and essential hypertensive  
patients.  
Clin Sci 68:179-184, 1985.

Bühler FR, Bolli P, Erne P, Kiowski W, Müller FB, Hulthén UL,  
Ji BH:  
Adrenoceptors, calcium, and vasoconstriction in normal and  
hypertensive humans.  
J Cardiovasc Pharmacol 7 [Suppl 6]: S130, 1985.

Bühler FR, Kiowski W, Bolli P, Müller FB, Jones RC:  
The β- and α-adrenoceptor response adaption in hypertension  
development.  
J Cardiovasc Pharmacol 10 [Suppl 4]:S76, 1987.

de Champlain J:  
The contribution of the sympathetic nervous system to arterial  
hypertension.  
Canad J Physiol Pharmacol 56:341-353, 1978.

Carafoli E:  
Calcium-transporting system of plasma membranes, with special  
attention to their regulation.  
Adv Cycl Nucl Res 17:543-549, 1984.

Carlson E, Hedberg A:  
Are cardiac effects of noradrenaline and adrenaline mediated by  
different β-adrenoceptors?  
Acta Physiol Scand (Suppl 440):47, 1976.

de Clerck F, Xhonseux B, Leysen J, Janssen PAJ:  
Evidence for functional 5-HT<sub>2</sub> receptor sites on human blood  
platelets.  
Biochem Pharmacol 33:2807-2811, 1984.

Dale HH:  
On some physiological actions of ergot.  
J Physiol (London) 34:163-206, 1906.

Dale HH:  
On the action of ergotoxin; with special reference to the  
existence of sympathetic vasodilatators.  
J Physiol (London) 46:291-300, 1913.

Dickinson KEJ, McKernan RM, Miles CMM, Leys KS, Sever PS:  
Heterogeneity of mammalian  $\alpha_2$ -adrenoceptors delineated by  
 $^3$ H-yohimbine binding.  
Eur J Pharmacol 120:258, 1986.

Diehl J, Kraft K, Stumpe KO:  
Retardment of development of hypertension in the spontaneously  
hypertensive rat by longterm kappa-opioid receptor antagonism.  
In: Stumpe KO, Kraft K, Faden AI: Opioid peptides and blood  
pressure control.  
Springer Verlag Berlin 168-173, 1988.

Diop L, Parini A, Dausse JP, Ben-Ishay D:  
Cerebral and renal  $\alpha$ -adrenoceptors in Sabra hypertensive and  
normotensive rats: effects of high-sodium diet.  
J Cardiovasc Pharmacol 6:S742-S747, 1984.

Distler A, Philipp Th, Lueth B, Wucherer G:  
Studies on the mechanism of mineralocorticoid-induced blood  
pressure increase in man.  
Clin Sci 57:303s-305s, 1979.

Dixon RAF, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG,  
Frielle T, Bolanowski MA, Benett CD, Rands E, Diehl RE, Mumford  
RA, Slater EE, Sigal IS, Caron MG, Lefkowitz RJ, Strader CD:  
Cloning of the gene and cDNA for mammalian  $\beta$ -adrenergic receptor  
and homology with rhodopsin.  
Nature 321:75, 1986.

Docherty JR, McGrath JC:  
A comparison of pre- and post-junctional potencies of several  
alpha-adrenoceptor agonists in the cardiovascular system and  
anococcygeus muscle of the rat.  
Naunyn Schmiedebergs Arch Pharmacol 312:107-116, 1980.

Doyle AE, Fraser JRE, Marshall RJ:  
Reactivity of forearm vessels to vasoconstrictor substances in  
hypertensive and normotensive subjects.  
Clin Sci 18:441-446, 1959.

Drew GM, Whiting SB:  
Evidence for two distinct types of postsynaptic  $\alpha$ -adrenoceptor  
in vascular smooth muscle *in vivo*.  
Br J Pharmacol 67:207-215, 1979.

Ebashi S, Mikawa T, Hirata M, Nonomura Y:  
The regulatory role of calcium in muscle.  
Ann NY Acad Sci 307:451-461, 1978.

Erne P, Bolli P, Bürgisser E, Bühler FR:  
Correlation of platelet calcium with blood pressure. Effects of  
antihypertensive therapy.  
N Engl J Med 310:1084-1088, 1984.

Erne P, Resink TJ, Bürgisser E, Bühler FR:  
Platelets and hypertension.  
J Cardiovasc Pharmacol 7 [Suppl 6]:103-108, 1985.

Fabris B, Fischetti F, Bulli G, Giraldi T, Castellano M, Beschi MG, Caretta R:  
Regulation of platelet alpha<sub>2</sub> adrenergic receptors in a population of patients with essential arterial hypertension and in normotensive subjects.  
G Ital Cardiol 21(7):717-723, 1992.

Farsang C, Kunos G:  
Naloxone reverses the antihypertensive effect of clinidine.  
Br J Pharmacol 67:161-164, 1979.

Feinleib M, Garrison R, Borhani N, Rosenmann R, Christian J:  
Studies of hypertension in twins.  
Epidemiology and control of hypertension. (Editor: Paul O)  
Georg Thieme Verlag, Stuttgart, 1-20, 1974.

Feinstein HB, Walenga R:  
The role of calcium in platelet activation.  
In: Becker EL, Simon AS, Austen KF (eds): Biochemistry of the acute allergic reaction.  
New York: Alan R. Riss 279-293, 1981.

Feinstein MB, Sha'afi RI: Role of Ca<sup>2+</sup> in arachidonic acid metabolism and in the action of arachidonic acid derived metabolites.  
In: Cheung WY (eds): Calcium and cell function.  
Vol.IV New York: Academic Press 337-377, 1983.

Feuerstein G, Zerbe RL, Faden AI:  
Opiate receptors and cardiovascular control in conscious SHR and WKY rats.  
Hypertension 5:663-671, 1983a.

Feuerstein G, Molineaux CJ, Rosenberger JG, Faden AI, Cox BM:  
Dynorphins and Leu-enkephalin in brain nuclei and pituitary of  
WKY and SHR.  
Peptides 4:225-229, 1983b.

Fitzgerald DJ, Doyle V, O'Brien ET, Kelly JG, O'Malley K:  
Beta-adrenoceptor density and responsiveness in borderline  
hypertension.  
J Hypertension 1 [Suppl 2]:260-262, 1983.

Folkow B:  
Physiological aspects of primary hypertension.  
Physiol Rev 62:347-504, 1982.

Folkow B, Karlström G:  
Vascular reactivity in hypertension: importance of structural  
influences.  
J Cardiovasc Pharmacol 10 [Suppl 4]:S25-S30, 1987.

Forder J, Scriabine A, Rasmussen H:  
Plasma membrane calcium flux, protein kinase C activation and  
smooth muscle contraction.  
J Pharmacol Exp Ther 235:267-273, 1985.

Fraser J, Nadeau J, Robertson D, Wood AJJ:  
Regulation of human leucocyte beta-receptor by endogenous  
catecholamines. Relationship of leucocyte beta-receptor density  
to the cardiac sensitivity to isoproterenol.  
J Clin Invest 67:1777-1784, 1981.

Freis ED:  
Salt, volume and the prevention of hypertension.  
Circulation 53:589-595, 1976.

Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ,  
Kobilka BK:  
Cloning of the cDNA for the human  $\beta_1$ -adrenergic receptor.  
Proc Natl Acad Sci 84:7920, 1987.

Frishman WH:  
Beta-adrenergic blocker withdrawal.  
Am J Cardiol 59:26F-32F, 1987.

Fritschka E, Distler A, Lenz Th, Kribben A, Schudrowitsch L,  
Philipp Th:  
Effect of nifedipine and verapamil on alpha-receptor activation  
in patients with essential hypertension.  
J Hypertens [Suppl 3]:535-537, 1984.

Fritschka E, Kribben A, Hoyer J, Schudrowitsch L, Distler A, Philipp Th:  
Adrenerge Rezeptoren bei Patienten mit essentieller Hypertonie.  
Einfluss von Alter und familiärer Belastung.  
Hochdruck 6:43-44, 1985.

Fritschka E, Kribben A, Schudrowitsch L, Hoyer J, Thiede HM, Distler A:  
Alpha<sub>2</sub>-adrenoceptor density in patients with essential hypertension: impact of a family history of hypertension.  
Clin Exp Hypertension A8(1):140, 1986a.

Fritschka E, Kribben A, Schudrowitsch L, Thiede HM, Philipp Th:  
Family history determines adrenoceptor density of patients with essential hypertension.  
Eur J Clin Invest 16(2):A16, 1986b.

Fritschka E, Kribben A, Schudrowitsch L, Thiede HM, Distler A, Philipp Th:  
Adrenozeptoren und essentielle Hypertonie. Bedeutung einer genetischen Disposition.  
Klin Wschr 64[Suppl 5]:209, 1986c.

Fritschka E, Kribben A, Haller H, Lüdersdorf M, Thiede HM, Hoyer J, Schudrowitsch L, Distler A, Philipp Th:  
Sympathetic activity and intracellular free calcium as related to a family history of hypertension.  
Nieren und Hochdruckkrankheiten 15:396, 1986d.

Fritschka E, Kribben A, Harwig S, Haller H, Lenz T, Thiede HM, Lüdersdorf M, Philipp Th, Distler A:  
Effect of fludrocortisone on adrenoceptors and free intracellular calcium in man.  
In: Middeke M, Holzgreve H (eds) New Aspects in Hypertension: Adrenoceptors;  
Springer-Verlag, Berlin Heidelberg New York p146-p154, 1986e.

Fritschka E, Kribben A, Haller H, Hoyer J, Thiede HM, Distler A, Philipp Th:  
Familial aggregation of altered adrenoceptor density and free intracellular calcium in patients with essential hypertension.  
J Cardiovasc Pharmacol 10 [Suppl 4]:S122-S125, 1987a.

Fritschka E, Kribben A, Hoyer J, Thiede HM, Distler A, Philipp Th:  
Genetischer Einfluß auf α<sub>2</sub>-adrenerge Rezeptoren und Adenylzyklaseaktivität bei Normotonikern und Hypertonikern.  
Klin Wochenschr 65 [Suppl IX]:170-171, 1987b.

Fritschka E, Philipp Th:  
Role of adrenergic receptors in essential hypertension.  
In: Bruschi G, Borghetti A (eds) Cellular aspects of  
hypertension:  
Springer-Verlag Berlin Heidelberg pp 245-255, 1991.

Fukuda K, Kuchii M, Hano T, Mohara O, Miyamoto Y, Nishio I,  
Masuyama Y:  
Changes in renal  $\alpha_2$ -adrenoceptors in experimental hypertension  
in rats.  
Jap Circ J 47:1221-1226, 1983.

Furchtgott RF:  
The pharmacological differentiation of adrenergic receptors.  
Ann NY Acad Sci 139:553, 1967.

Furchtgott RF:  
The classification of adrenoceptors (adrenergic receptors). An  
evaluation from the standpoint of receptor theory.  
In: Blaschko H, Muscholl E (eds) Handbook of Experimental  
Pharmacology  
Vol 33: Catecholamines Springer, Berlin Heidelberg New York pp  
283-335, 1972.

Ganguly P, Sonnichsen WJ:  
Interaction of thrombin with human platelets.  
Br J Haematol 29:617-626, 1975.

Gauss CF:  
Theoria motus corporum coelestium in sectionibus conicis solem  
ambientium.  
Lib II, Sect III, Hamburgi Sumtibus, Perthes F et Besser IH,  
1809.

Giudicelli Y, Lacasa D, Agli B, Leneveu A:  
Comparison of changes in the characteristics of  $\beta$ -adrenoceptors  
and responsiveness of human circulating lymphocytes during  
chronic and after chronic administration of pindolol and  
propranolol.  
Eur J Clin Pharmacol 26:7-12, 1984.

Glaubiger G, Lefkowitz RJ:  
Elevated beta-adrenergic receptor number after chronic  
propranolol treatment.  
Biochem Biophys Res Commun 78:720-825, 1977.

Goetz KL, Wang BC, Madwed JB, et al.:  
Cardiovascular, renal, and endocrine responses to intravenous  
endothelin in conscious dogs.  
Am J Physiol 255:R1064-R1068, 1988.

**Goldstein DS:**  
Plasma catecholamines and essential hypertension. An analytical review.  
*Hypertension* 5:86-99, 1983.

**Gopinath RM, Vincenzi FF:**  
Phosphodiesterase protein activator mimics red blood cell cytoplasmatic activator of  $\text{Ca}^{2+}$ - $\text{Mg}^{2+}$ -ATPase.  
*Biochem Biophys Res Commun* 77:1203-1209, 1977.

**Grand JA, Scrutton MC:**  
Novel  $\alpha_2$ -adrenoceptors primarily responsible for inducing platelet aggregation.  
*Nature* 217:659-661, 1979.

**Grim CE, Luft FC, Miller JZ, Brown PL, Gannon MA, Weinberger MH:**  
Effects of sodium loading and depletion in normotensive first-degree relatives of essential hypertensives.  
*J Lab Clin Med* 94:764-771, 1979.

**Haddy FJ, Overbeck HW:**  
The role of humoral agents in volume expanded hypertension.  
*Life Sci* 19:935-947, 1976.

**Haller H, Lenz T, Thiede M, Lüdersdorf M, Kribben A, Distler A, Philipp Th:**  
Platelet intracellular free calcium and hypertension.  
*J Clin Hypertens* 3(1):12-19, 1987.

**Hamilton M, Pickering GW, Fraser Roberts JA, Sowry GSC:** The ethiology of essential hypertension. 4. The role of inheritance.  
*Clin Sci* 13:273-304, 1954.

**Hamet P, Skuherska R, Pang SC, Tremblay J:**  
Abnormalities of platelet function in hypertension and diabetes.  
*Hypertension* 7 [Suppl II]:II-113 - II-142, 1985.

**Harden TK:**  
Agonist-induced desensitization of the  $\beta$ -adrenergic receptor-linked adenylylate cyclase.  
*Pharmacol Rev* 35:5-32, 1983.

**Harder DR:**  
Pressure-induced myogenic activation of cat cerebral arteries is dependent on intact endothelium.  
*Circ Res* 60:102-107, 1987.

Harmon JT, Jamieson GA:  
Activation of platelets by alpha-thrombin is a receptor mediated event.  
J Biol Chem 261:15928-15933, 1986.

Hassen AH, Feuerstein G, Pfeiffer A, Faden AI:  
Delta versus mu receptors: cardiovascular and respiratory effects of opiate agonists microinjected into nucleus tractus solitarius of cats.  
Regul Pept 4:299-309, 1982.

Hassen AH, Feuerstein G, Faden AI:  
Differential cardiovascular effects mediated by mu and kappa opiate receptors in hindbrain nuclei.  
Peptides 4:621-625, 1983.

Hassen AH, Feuerstein G, Faden AI:  
Kappa opioid receptors modulate cardiorespiratory function in hindbrain nuclei of the rat.  
J Neurosci 4:2213-2221, 1984.

Hathaway DR, Adelstein RS:  
Human platelet myosin light chain kinase requires the calcium-binding protein calmodulin for activity.  
Proc Natl Acad Sci USA 76:1653-1657, 1979.

Hedberg A, Gerber JG, Nies AS, Wolfe BB, Molinoff PB:  
Effects of pindolol and propranolol on  $\beta$ -adrenergic receptors on human lymphocytes.  
J Pharmacol Exp Ther 239:117-123, 1986.

Hermsmeyer K:  
Altered arterial muscle ion transport mechanism in the spontaneously hypertensive rat.  
J Cardiovasc Pharmacol 6:S10-15, 1984.

Hicks PE, Langer SZ:  
Is Idaxon a partial agonist at presynaptic inhibitory  $\alpha_1$ -receptors in SHR tail arteries.  
Br J Pharmacol 84 [Suppl]: 67P, 1985.

Hinssen H, D'Haese J, Small JV, Sobieszek A:  
Mode of filament assembly of myosin from muscle and non muscle cells.  
J Ultrastruct Res 64:282-302, 1978.

Höglinger O, Kotanko P, Zinke W, Herg M, Kenner T, Skrabal F:  
Molecular Biology of the human  $\beta_2$ -Adrenoceptor (AR).  
J Hypertens 10 [Suppl 4] S90, 1992.

Hoffmann BB, Lefkowitz RJ:  
Radio-ligand binding studies of adrenergic receptors: new insights into molecular and physiological regulation.  
Annu Rev Pharmacol Toxicol 20:581-608, 1980.

Hoyer J, Fritschka E, Kribben A, Thiede HM, Distler A,  
Philipp Th:  
Familiäre Hochdruckbelastung, Adenylzyklaseaktivität und  
 $\alpha_2$ -adrenerge Rezeptoren.  
Hochdruck 8:43, 1986.

Hsu CY, Knapp DR, Halushka PV:  
The effects of alpha adrenergic agents on human platelet aggregation. J Pharmacol Exp Ther 208:366-370, 1979.

Illes P, Pfeiffer N:  
Regulation of blood pressure by peripheral opioid mechanisms.  
Elsevier Science Publishers BV pp175-180, 1985.

Inoue A, Yanagisawa M, Kimura et al.:  
The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes.  
Proc Natl Acad Sci USA 86:2863-7, 1989.

Jakobs KH, Saur W, Schulz G:  
Reduction of adenylate cyclase activity in lysates of human platelets by the alpha-adrenergic compound of epinephrine.  
J Cyclic Nucleotide Protein Phosphor Res 2:381-392, 1976.

Jarrett HW, Penniston JT:  
Partial purification of the  $\text{Ca}^{2+}$ - $\text{Mg}^{2+}$ -ATPase activator of 3':5'-cyclic nucleotide phosphodiesterase.  
Biochem Biophys Res Commun 77:1210-1216, 1977.

Jie K, van Brummelen P, Vermey P, Timmermans PBMWM, van Zwieten PA:  
 $\alpha_1$ - and  $\alpha_2$ -adrenoceptor mediated vasoconstriction in the forearm of normotensive and hypertensive subjects.  
J Cardiovasc Pharmacol 8:190-196, 1986.

Jie K, van Brummelen P, Vermey P, Timmermans PBMWM, van Zwieten PA:  
Postsynaptic  $\alpha_1$ - and  $\alpha_2$ -adrenoceptors in human blood vessels: interactions with exogenous and endogenous catecholamines.  
Eur J Clin Invest 17:174-181, 1987.

Jones CR, Elliott HL, Deighton N, Howie CA, Reid JL:  
Alpha-adrenoceptor number and funktion in platelets from treated  
and untreated patients with essential hypertension and age- and  
sex-matched controls.  
*J Hypertens* 3 [Suppl 3]:S153-S156, 1985.

Kafka MS, Lake CR, Gullner H-G, Tallman JF, Bartter FC,  
Fujita T:  
Adrenergic receptor function is different in male and female  
patients with essential hypertension.  
*Clin Exp Hypertens* 1:613-627, 1979.

Kaibuchi K, Takai Y, Sawamura M, Hoshijima M, Fujikura T,  
Nishizuka Y:  
Synergistic function of protein phosphorylation and calcium  
mobilisation in platelet activation.  
*J Biol Chem* 258:6701-6704, 1983.

Kamm KE, Stull JT:  
The function of myosin and myosin light chain kinase  
phosphorylation in smooth muscle.  
*Ann Rev Pharmacol Toxicol* 25:593-620, 1985.

Kanczik R, Michel MC, Khamssi M, Knorr A, Brodde O-E:  
 $\alpha$ - und  $\beta$ -Adrenozeptoren bei Hypertonie:  
Kardiale und renale  $\alpha_1$ -Adrezeptoren in Tiermodellen der  
erworbenen Hypertonie (Abstract).  
*Hochdruck* 7:40-42, 1987.

Keeton TK, Campell WB:  
The pharmacologic alteration of renin release.  
*Pharmacol Rev* 32:81-227, 1980.

Kent RS, DeLean A, Lefkowitz RJ:  
A quantitative analysis of beta-adrenergic receptor  
interactions: resolution of high and low affinity states of the  
receptor by computer modeling of ligand binding data.  
*Mol Pharmacol* 14:17-23, 1980.

Khatchaturian H, Lewis ME, Schäfer MK-H, Watson SJ:  
Anatomy of the CNS opioid system.  
*Trends Neurosci* 8:111-119, 1985.

Kikkawa U, Nishizuka Y:  
Protein kinase C.  
In: Krebs ED, Boyer PD (eds): *The enzymes*.  
New York: Academic Press 167-189, 1986.

Klaus D, Antoni D, Lederle RM, Lemke R:  
Ionisiertes Kalzium im Blut bei essentieller Hypertonie.  
Nieren- und Hochdruckkrankheiten 13:324-327, 1984.

Kobilka BK, Dixon RAF, Frielle T, Dohlmann HG, Bolanowski MA,  
Sigal IS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ:  
cDNA for the human  $\beta_2$ -adrenergic receptor: a protein with  
multiple membrane spanning domains and encoded by a gene whose  
chromosomal location is shared with that of the receptor for  
platelet derived growth factor.  
Proc Natl Acad Sci 84:46, 1987a.

Kobilka BK, Frielle T, Dohlmann HG, Bolanowski MA, Dixon RAF,  
Keller P, Caron MG, Lefkowitz RJ:  
Delineation of the intronless nature of the genes for the human  
and hamster  $\beta_2$ -adrenergic receptor and their putative promotor  
regions.  
J Biol Chem 262(15):7321, 1987b.

Kobilka BK, Matsui H, Kobilka TS, Yang-Feng TL, Francke U,  
Caron MG, Lefkowitz RJ, Regan JW:  
Cloning, sequencing, and expression of the gene coding for the  
human platelet  $\alpha_2$ -adrenergic receptor.  
Science 238:650-656, 1987c.

Kotanko P, Skrabal F, Gruber G, Doll P, Meister B:  
Adrenergic receptors and sodium reabsorption in normotensive  
subjects as related to salt sensitivity.  
J Clin Exp Hypertens 9 [Suppl 1]:307-318, 1987.

Kotanko P, Höglinder O, Zinke W, Herg M, Herg M, Skrabal F:  
Cultured fibroblasts of patients with essential hypertension  
(EH) express a reduced number of  $\beta_2$ -Adrenoceptors (AR).  
J Hypertens 10 [Suppl 4]:S90, 1992.

Kesteloot H, Geboers J:  
Calcium and blood pressure.  
Lancet 1:813-815, 1983.

Komuro I, Kurihara H, Sugiyama T, Takaku F, Yazaki Y:  
Endothelin stimulates c-fos and c-myc expression and  
proliferation of vascular smooth cells.  
FEBS Lett 238:249-252, 1988.

Korotkoff NS:  
On the subject of methods of measuring blood pressure.  
Bull Imp Med Mil Imp Academy St. Petersburg 11:365, 1905.

Kosterlitz HW, Patterson SJ, Robson LE:  
Characterization of the kappa-subtype of the opiate receptor in  
the guinea pig brain.  
Br J Pharmacol 73:939-949, 1981.

Kraft K, Lang RE, Kirilov G, Kolloch R, Unger T, Yadel Y,  
Ganten D:  
Effect of denervation on the leucine-enkephalin content of the  
adrenal gland of spontaneously hypertensive rats (SHR).  
Clin and Exper - Theory and Practice. A6(10&11) 2059-2062, 1984.

Kraft K, Theobald R, Stumpe KO:  
Clonidine normalizes low plasma beta-endorphin concentration and  
blood pressure in young men with mild essential hypertension.  
Klin Wochenschr 64:738-741, 1986.

Kraft K, Theobald R, Kolloch R, Stumpe KO:  
Normalization of blood pressure and plasma concentrations of  
beta-endorphin and leucine-enkephaline in patients with primary  
hypertension after treatment with clonidine.  
J Cardiovasc Pharmacol 10 [Suppl 12]:S147-S151, 1987.

Kraft K, Behrendt M, Kolloch R, Stumpe KO:  
Reduced  $\beta$ -endorphin secretion in young patients with mild  
essential hypertension at rest and during exercise.  
J Hypertens 6 [Suppl 4]:S381-S383, 1988.

Kunos G, Farsang C, Ramirez-Gonzalez MD:  
 $\beta$ -Endorphin: possible involvement in the antihypertensive effect  
of central  $\alpha$ -receptor activation.  
Science 211:82-84, 1981.

Kunos G, Hirata F, Ishac EJ, Tchakarov L:  
Time-dependent conversion of alpha 1 - to beta-adrenoceptor-  
mediated glycogenolysis in isolated rat liver cells: role of  
membrane phospholipase A2.  
Proc Natl Acad Sci (USA) 81:6178-6182, 1984.

Kunos G, Mosqueda-Garcia R, Mastrianni JA:  
Endorphinergic neurons in the brainstem and the control of blood  
pressure and heart rate.  
In: Illes P, Farsang C (eds):  
Regulatory roles of opioid peptides.  
Weinheim: Verlag Chemie pp460-470, 1988.

Kuriyama H, Ito Y, Suzuki H, Kitamura K, Itoh T:  
Factors modifying contraction-relaxation cycle in vascular  
smooth muscles.  
Am J Physiol 243:H641-662, 1982.

Langer SZ:  
Presynaptic regulation of catecholamine release.  
Biochem Pharmacol 23:1793, 1974.

Langer SZ:  
The role of  $\alpha$ - and  $\beta$ -presynaptic receptors in the regulation of noradrenaline release elicited by nerve stimulation.  
Clin Sci Mol Med 51:423s-426s, 1976.

Langer SZ, Hicks PE:  
Alpha-adrenoceptor subtypes in blood vessels: physiology and pharmacology.  
J Cardiovasc Pharmacol 6:S547-S558, 1984.

Lands AM, Arnold A, Mc Auliff JP, Luduena FP, Brown TC:  
Differentiation of receptor systems activated by sympathomimetic amines.  
Nature 214:597, 1967a.

Lands AM, Luduena FP, Buzzo HJ:  
Differentiation of receptors responsive to isoproterenol.  
Life Sci 6:2241, 1967b.

Laubie M, Schmitt H, Vincent M, Remond G:  
Central cardiovascular effects of morphinomimetic peptides in dogs.  
Eur J Pharmacol 46:67-71, 1977.

Leeb-Lundberg LMF, Cotecchia S, DeBlasi A, Caron MG,  
Lefkowitz RJ:  
Regulation of adrenergic receptor function by phosphorylation.  
I. Agonist-promoted desensitization and phosphorylation of  $\alpha_1$ -adrenergic receptors coupled to inositol phospholipid metabolism in DDT<sub>1</sub> MF-2 smooth muscle cells.  
J Biol Chem 262:3098-3105, 1987.

Lefkowitz RJ:  
Identifikation and regulation of alpha- and beta-adrenergic receptors.  
Fed Proc 37:123-129, 1978.

Lefkowitz RJ, Caron MG:  
Adrenergic receptors: molecular mechanisms of clinically relevant regulation.  
Clin Res 33:395-405, 1985.

Lefkowitz RJ, Caron MG:  
Regulation of adrenergic receptor function by phosphorylation.  
J Mol Cell Cardiol 18:885-895, 1986.

Litosch I, Fain JN:  
Regulation of phosphoinositide breakdown by guanine nucleotides.  
Life Sci 39:187-194, 1986.

Londe S, Bourgoignie JJ, Robson AM, Goldring D:  
Hypertension in apparently normal children.  
J Pediatr 78:569-577, 1971.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ:  
Protein measurement with the Folin phenol reagent.  
J Biol Chem 193:265-275, 1951.

MacIntyre DE, Gordon JL:  
Discrimination between platelet prostaglandin receptors with a  
specific antagonist of bisenoic prostaglandins.  
Throm Res 11:705-713, 1977.

Mann JFE, Sis J, Ritz E:  
<sup>125</sup>I-angiotensin II binding to human blood cells.  
J Hypertension 3:131-137, 1985.

Marquis NR, Becker JA, Vigdahl RI:  
An epinephrine induced decrease in cyclic AMP synthesis.  
Biochem Biophys Res Commun 39:783-789, 1970.

Martin PR, Ebert MH, Gordon KE, Linnoila M, Kopin IJ:  
Effects of clonidine on central and peripheral catecholamine  
metabolism.  
Clin Pharmacol Ther 35:322-327, 1984.

McCarron DA, Pingree PA, Rubin RJ, Gaucher SM, Molitch M,  
Krutzik S:  
Enhanced parathyroid function in essential hypertension: a  
homeostatic response to a urinary calcium leak.  
Hypertension 2:162-168, 1980.

McCarron DA:  
Low serum concentrations of ionized calcium in patients with  
hypertension.  
N Eng J Med 307:226-228, 1982.

McCarron DA:  
Is calcium more important than sodium in the pathogenesis of  
essential hypertension?  
Hypertension 7:607-627, 1985.

McCubbin JY, Surwit RS, Williams RB:  
Endogenous opiate peptides, stress reactivity and risk for  
hypertension.  
Hypertension 7:808-811, 1985.

McLean AJ, Dusouich P, Barron KW, Briggs AH:  
Interaction of hydralazine with tension development and  
mechanisms of calcium accumulation in K<sup>+</sup>-stimulated rabbit  
aortic strips.  
J Pharmacol Exp Ther 207:40-48, 1978.

McMahon EG, Palomo MA, Moore WM:  
Phosphoramidon blocks the pressor activity of big endothelin  
[1-39] and lowers blood pressure in spontaneously hypertensive  
rats.  
J Cardiovasc Pharmacol 17:S29-33, 1991.

Miall WE, Oldham PD:  
The hereditary factor in arterial blood pressure.  
Brit med J 1:75, 1963.

Michel MC, Galal O, Wang XL, Beckeringh JJ, Bock KD, Brodde O-E:  
 $\alpha_2$ - und  $\beta_2$ -Adrenozeptoren bei normotonen Kindern essentieller  
Hypertoniker und: ein Modell zur Pathogenese der genetisch  
determinierten essentiellen Hypertonie (Abstract).  
Hochdruck 7:34-35, 1987.

Michel MC, Insel PA:  
Are there multiple imidazoline binding sites?  
Trends Pharmacol Sci 10:342-344, 1989.

Michel MC, Galal O, Stoermer J, Bock KD, Brodde O-E:  
 $\alpha$ - and  $\beta$ -Adrenoceptors in Hypertension. II, Platelet  $\alpha_2$ - and  
lymphocyte  $\beta_2$ -adrenoceptors in children of parents with essential  
hypertension. A model for the pathogenesis of the genetically  
determined hypertension.  
J Cardiovasc Pharmacol 13:432-439, 1989.

Middeke M, Remien J, Holzgreve H:  
The influence of sex, age, blood pressure and physical stress on  
 $\beta_2$ -adrenoceptor density in mononuclear cells.  
J Hypertens 2:261-264, 1984.

Middeke M, Remien J, Kirzinger S, Holzgreve H:  
Adrenergic hyporesponsiveness during long-term diuretic therapy - a  
possible explanation for the antihypertensive effect of  
diuretics?  
Eur J Pharmacol 109:401-403, 1985.

Miller WL, Redfield MM, Burnett JC Jr:  
Integrated cardiac, renal, and endocrine actions of endothelin.  
J Clin Invest 83:317-320, 1989.

- Mills DCB:  
Initial biochemical response of platelets to stimulation.  
CIBA Foundation Symposium, No 35 (new series), Amsterdam  
153-167, 1975.
- Minneman KP, Pittman RN, Molinoff PB:  
 $\beta$ -Adrenergic receptor subtypes: properties, distribution and regulation.  
Annu Rev Neurosci 4:419-461, 1981.
- Molinoff PB, Aarons RD:  
Effects of drugs on  $\beta$ -adrenergic receptors on human lymphocytes.  
J Cardiovasc Pharmacol 5 [Suppl 1]:S63-S67, 1983.
- Moore TJ, Williams GH:  
Angiotensin II receptors on human platelets.  
Circ Res 51:314-320, 1982.
- Motulsky HJ, Insel PA:  
[<sup>3</sup>H]Dihydroergocryptine binding to alpha-adrenergic receptors of human platelets. A reassessment using the selective radioligands [<sup>3</sup>H]prazosin, [<sup>3</sup>H]yohimbine, [<sup>3</sup>H]rauwolscine.  
Biochem Pharmacol 31:2591-2597, 1982.
- Motulsky HJ, O'Connor DT, Insel PA:  
Platelet  $\alpha_2$ -adrenergic receptors in treated and untreated essential hypertension.  
Clin Sci 64:265-272, 1983.
- Myers J, Morgan T:  
The effect of sodium intake on the blood pressure related to age and sex.  
Clin Exp Hypertension A5 (1):99-188, 1983.
- Newman KD, Williams LT, Bishopric NH, Lefkowitz RJ:  
Identification of alpha-adrenergic receptors in human platelets by <sup>3</sup>H-dihydroergocryptine binding.  
J Clin Invest 61:395-402, 1978.
- Niedermann R, Pollard TD:  
Human platelet myosin II, in vitro assembly and structure of myosin filaments.  
J Cell Biol 67:72-92, 1975.
- Nigilli V, Siegel E, Carafoli E:  
The purified  $\text{Ca}^{2+}$ -pump of human erythrocyte membranes catalyses an electroneutral  $\text{Ca}^{2+}$ -  $\text{H}^+$ -exchange in reconstituted liposomal systems.  
J Biol Chem 257:2350-2356, 1982.

- Nishizuka Y:  
Turnover of inositol phospholipids and signal transduction.  
Science 225:1365-1370, 1984.
- Okumura T, Hasitz M, Jamieson GA:  
Platelet glycoprotein IIb/IIIa. Interactions with thrombin and role as thrombin receptor.  
J Biol Chem 253:3435-3443, 1978.
- Oshima T, Young EW, Bukoski RD, McCarron DA:  
Abnormal calcium handling by platelets of spontaneously hypertensive rats.  
Hypertension 15 (6 Pt 1):606-611, 1990.
- Palmer RMJ, Ferrige AG, Moncada S:  
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.  
Nature 327:524-526, 1987.
- Pasanisi F, Sloan L, Rubin PC:  
Cardiovascular properties of metkephamid, a delta opioid receptor agonist, in man.  
Clin Sci 68:209-213, 1985.
- Pettibone DJ, Mueller GP:  
Clonidine releases immunoreactive  $\beta$ -endorphin from rat pars distalis.  
Brain Res 221:409-414, 1981.
- Pettinger WA, Sanchez A, Saavedra J, Haywood JR, Gandler T, Rodes T:  
Altered renal alpha<sub>2</sub>-adrenergic receptor regulation in genetically hypertensive rats.  
Hypertension 4 [Suppl II]:II-188-II-192, 1982a.
- Pettinger WA, Gandler T, Sanchez A, Saavedra JM:  
Dietary sodium and renal  $\alpha_2$ -adrenergic receptors in Dahl hypertensive rats.  
Clin Exp Hypertens A4:819-828, 1982b.
- Pettinger WA:  
Renal  $\alpha_2$ -adrenergic receptors and hypertension.  
Hypertension 9:3-6, 1987.
- Petty MA, de Jong W:  
Cardiovascular effects of beta-endorphin after microinjection into the nucleus tractus solitarii of the anaesthetized rat.  
Eur J Pharmacol 81:449-457, 1982.

Pfeiffer A, Pfeiffer DG, Feuerstein G, Faden AI, Kopin IJ:  
An increase in opiate receptor sites is associated with enhanced  
cardiovascular depressant but not respiratory depressant action  
of morphine.  
Brain Res 296:305-311, 1984.

Pfeuffer T, Helmreich EJM:  
Activation of pigeon erythrocyte membrane adenylate cyclase by  
guanylnucleotide analogues and separation of a nucleotide  
binding protein.  
J Biol Chem 250:867-876, 1975.

Philipp Th, Cordes U, Distler A:  
Sympathetic nervous system and blood pressure control in  
essential hypertension.  
Lancet II:959-963, 1978.

Philipp Th:  
Sympathetic nervous activity in essential hypertension: activity  
and reactivity.  
J Cardiovasc Pharmacol 10 [Suppl 4]:S31-S35, 1987.

Postnov JV:  
Alteration of cell membrane control over intracellular calcium  
in essential hypertension and in spontaneously hypertensive  
rats.  
In: Laragh JH, Buckler FR, Seldin DW (eds): Frontiers in  
hypertension research.  
New York: Springer Verlag, S91-93, 1981.

da Prada M, Zürcher G:  
Simultaneous radioenzymatic determination of plasma and tissue  
adrenaline, noradrenaline and dopamine within the femtomole  
range.  
Life Sci 19:1161-1174, 1976.

Prichard BNC, Tomlinson B, Walden RJ, Bhattacharjee P:  
The  $\beta$ -adrenergic blockade withdrawal phenomenon.  
J Cardiovasc Pharmacol 5 [Suppl 1]:S56-S62, 1983.

Rasmussen H:  
The calcium second messenger system, II.  
N Engl J Med 314:1164-1170, 1986a.

Rasmussen H:  
The calcium messenger system, I.  
N Engl J Med 314:1094-1101, 1986b.

Rasmussen H, Kojima J, Kojima K, Zawallich W, Apfeldorf W:  
Calcium as second messenger: sensitivity modulation, C-kinase  
pathway and sustained response.

In: Greengard P, Robinson GA (eds): Advances in cyclic  
nucleotide and protein phosphorylation research.

Vol.18 New York: Raven Press, 159-193, 1984.

Rink TJ, Smith SW, Tsien RY:

Cytoplasmatic free calcium in human platelets: calcium threshold  
and calcium independent activation for shape change and  
aggregation.

FEBS Lett 148:21-26, 1982.

Rink TJ, Tsien RY, Sanches A, Hallam TJ:

Calcium and diacylglycerol: separable and interacting  
intracellular activators in human platelets.

In: Rubin RP, Weiss GB, Putney JW Jr (eds): Calcium in  
biological systems.

New York: Plenum Press, 155-164, 1985.

Robinson GA, Arnold A, Hartmann RC:

Divergent effects of epinephrine and prostaglandin E<sub>1</sub> on the  
level of cyclic AMP in human blood platelets.

Pharmacol Res Commun 1:325-332, 1969.

Robinson BF, Dobbs RJ, Bayley S:

Response of forearm resistance vessels to verapamil and sodium  
nitroprusside in normotensive and hypertensive men: evidence for  
a functional abnormality of vascular smooth muscle in primary  
hypertension.

Clin Sci 63:33-42, 1982.

Robinson BF:

Altered calcium handling as a cause of primary hypertension.  
J Hypertens 2:453-460, 1984.

Rodbell M, Birnbaumer L, Pohl SL, Krans HMJ:

The glucagon-sensitive adenyl cyclase system in plasma membranes  
of rat liver. V. An obligatory role of guanyl nucleotides in  
glucagon action.

J Biol Chem 246:1877-1882, 1971.

Romoff MS, Keusch G, Campese VM, Wang MS, Friedler RM,  
Weidmann P, Massry SG:

Effect of sodium intake on plasma catecholamines in normal  
subjects.

J Clin Endocrinol Metab 48:26-31, 1979.

Rose RJ, Miller JZ, Grim CE, Christian JC:  
Aggregation of blood pressure in the families of identical  
twins.  
Am J Epidemiol 109:503-511, 1979.

Rubin PC, Blaschke TF, Guilleminault C:  
Effect of naloxone, a specific opioid inhibitor, on blood  
pressure fall during sleep.  
Circulation 73:117-123, 1981.

Saiz J, Torres A, Martinez-Sierra R, Sanchez A:  
Altered renal  $\alpha$ -adrenoceptor regulation in DOCA-salt rats:  
chronic effects of  $\alpha_1$ - and  $\alpha_2$ -receptor blockers.  
Eur J Pharmacol 121:161-166, 1986.

Sakurai T, Yanagisawa M, Takuwa Y, et al.:  
Cloning of a cDNA encoding a non-isopeptide-selective subtype of  
the endothelin receptor.  
Nature (Lond) 348:732-5, 1990.

Sanchez A, Pettinger WA:  
Dietary sodium regulation of blood pressure and renal  $\alpha_1$ - and  
 $\alpha_2$ -receptors in WKY and SH rats.  
Life Sci 29:2795-2802, 1981.

Sanchez A, Vidal MJ, Martinez-Sierra R, Saiz J:  
Ontogeny of renal alpha-1 and alpha-2 adrenoceptors in the  
spontaneously hypertensive rat.  
J Pharmacol Exp Ther 237:972-979, 1986.

Scatchard G:  
The attraction of proteins for small molecules and ions.  
Ann NY Acad Sci 51:660, 1949.

Schloos J, Wellstein A, Palm D:  
Agonist binding at alpha<sub>2</sub>-adrenoceptors of human platelets using  
<sup>3</sup>H-UK-14,304: regulation by Gpp(NH)p and cations.  
Naunyn Schmiedeberg's Arch. Pharmacol 336:48-59, 1987.

Schultz G, Rosenthal W:  
Prinzipien der transmembranären Signalumsetzung bei der Wirkung  
von Hormonen und Neurotransmittern.  
Arzneim-Forsch 35:1879-1885, 1985.

Silver PJ, Stull JT:  
Regulation of myosin light chain and phosphorylase  
phosphorylation in tracheal smooth muscle.  
J Biol Chem 257:6145-6150, 1982.

Sitsen JMA, Van Ree JM, DeJong W:  
Cardiovascular and respiratory effects of beta-endorphin in  
anaesthetized and conscious rats.  
J Cardiovasc Pharmacol 4:883-888, 1982.

Skrabal F, Herholz H, Neumayr M, Hamberger L, Ledochowski M,  
Sporer H, Hortnagel H, Schwarz S, Schonitzer D:  
Salt sensitivity in humans is linked to enhanced sympathetic  
responsiveness and to enhanced proximal tubular reabsorption.  
Hypertension 6:152-158, 1984.

Skrabal F, Gruber G, Meister B, Ledochowski M, Doll P, Lang F,  
Cerny E:  
Salt sensitivity in normotensives with family history of  
hypertension: studies of membrane transport, intracellular  
electrolytes and  $\alpha_2$ -adrenergic receptors.  
J Hypertens. 3 [Suppl 3]:S25-S28, 1985.

Skrabal F, Kotanko P, Meister B, Doll P, Gruber G:  
Up-regulation of alpha<sub>2</sub> adrenoceptors and down-regulation of  
beta<sub>2</sub> adrenoceptors by high-salt diet in normotensive men:  
enhanced up-regulation of operative (alpha<sub>2</sub>:beta<sub>2</sub>) adrenoceptor  
ratio predicts salt sensitivity.  
J Hypertens 4[Suppl 6]:S196-S199, 1986.

Skrabal F, Kotanko P, Friedrich C:  
Inverse regulation of  $\alpha$ -2 and  $\beta$ -2 Adrenoceptors in salt-  
sensitive Hypertension: an hypothesis.  
Life Sci 45:2061-2076, 1989.

Sugiyama T, Yshizumi M, Takahu F, Urabe H, Tsukakoshi M, Kasuya  
T, Yazaki Y:  
The elevation of the cytoplasmatic calcium ions in vascular  
smooth cells in SHR - measurement of the free calcium ions in  
single living cells by lasermicrofluorospectrometry.  
Biochem Biophys Res Comuns 141:340-345, 1986.

Starke K, Borowski E, Endo T:  
Preferential blockade of presynaptic  $\alpha$ -adrenoceptors by  
yohimbine.  
Eur J Pharmacol 34:385, 1975.

Starke K:  
Regulation of Noradrenaline release by presynaptic receptor  
systems.  
Rev Physiol Biochem Pharmacol 77:1, 1977.

Starke K:  
Presynaptic receptors.  
Ann Rev Pharmacol Toxicol 21:7, 1981.

Steece KA, Lee Jm, Fields JZ, de Leon-Jones FA, Ritzmann RF:  
Differential down-regulation of delta opioids binding sites  
during physical dependence of methionine enkephalin in the rat.  
Life Sci 44:1449-1455, 1989.

Steer M, Wood A:  
Regulation of human platelet adenylate cyclase by epinephrine,  
prostaglandin E<sub>1</sub>, and guanine nucleotides.  
J Biol Chem 254: 10791-10797, 1979.

Stiles GL, Caron MG, Lefkowitz RJ:  
 $\beta$ -Adrenergic receptors: biochemical mechanisms of physiological  
regulation.  
Physiol Rev 64:661-743, 1984.

Strazullo P, Nunziata V, Cirillo M:  
Abnormalities of calcium metabolism in essential hypertension.  
Clin Sci 65:137-141, 1983.

Suematsu E, Hirata M, Hashimoto T, Kurijama H:  
Inositol 1,4,5-trisphosphate releases Ca<sup>2+</sup> from intracellular  
store sites in skinned singel cells of porcine coronary  
arteries.  
Biochem Biophys Res Commun 120:481-492, 1983.

Summers RJ:  
Renal  $\alpha$ -adrenoceptors.  
Fed Proc 43:2917-2922, 1984.

Thiede HM, Kehr W:  
Conjoint radioenzymatic measurement of catecholamines, their  
catechol metabolites and DOPA in biological samples.  
Naunyn Schmiedebergs Arch Pharmacol 318:19-28, 1981.

Tollefson DM, Feagler JR, Majerus PW:  
The binding of thrombin to the surface of human platelets.  
J Biol Chem 249:2646-2651, 1974.

Tsien RY, Pozzan T, Rink TJ:  
Calcium homeostasis in intact lymphocytes: cytoplasmic free  
calcium monitored with a new, intracellular trapped fluorescent  
indicator.  
J Cell Biol 94:325-334, 1982.

Umemura S, Uchino K, Yasuda G, Ishikawa Y, Hatori Y, Tochikubo  
O, Ishii M, Kaneko Y:  
Altered platelet alpha<sub>2</sub>-adrenoceptors and adrenaline response in  
adolescents with borderline hypertension who have a family  
history of essential hypertension.  
J Hypertens 6 [Suppl 4]:S568-S571, 1988.

Vale W, Vaughan J, Smith M, Yamamoto G, Rivier J, Rivier C:  
Effects of synthetic ovine-corticotropin-releasing factor,  
glucocorticoids, catecholamines, neurohypophyseal peptides and  
other substances on cultured corticotropic cells.  
Endocrinology 113:1121-1131, 1983.

Vane JR, Änggård EE, Botting RM:  
Regulatory functions of the vascular endothelium.  
N Engl J Med 323:27-36, 1990.

Walden RJ, Bhattacharjee P, Tomlinson B, Cashin J, Graham BR,  
Prichard BNC:  
The effect of intrinsic sympathomimetic activity on  $\beta$ -receptor  
responsiveness after  $\beta$ -adrenoceptor blockade withdrawal.  
Br J Clin Pharmacol 13 [Suppl 2]:359S-364S, 1982.

de Wardener HE, MacGregor GA:  
Dahl's hypothesis that a saluretic substance may be responsible  
for a sustained rise in arterial blood pressure: its possible  
role in essential hypertension.  
Kidney Int 18:1-9, 1980.

Warnock P, Docherty JR:  
Further investigation of the sites of vascular alpha<sub>1</sub> and alpha<sub>2</sub>  
adrenoceptors in the anaesthetised spontaneously hypertensive  
rat. J Cardiovasc  
Pharmacol 8:67-70, 1986.

Webb RC, Bohr DF:  
Recent advances in the pathogenesis of hypertension:  
consideration of structural, functional and metabolic vascular  
abnormalities resulting in elevated arterial resistance.  
Am Heart J 102:251-265, 1981.

Weber F, Anlauf M:  
Direkte und indirekte Vergleichsuntersuchungen zur  
Meßgenauigkeit des elektronischen Blutdruckmeßgerätes Tonomed®.  
Herz/Kreislauf 5/82:279-283, 1982.

Weber MA, Drayer JIM:  
The sympathetic nervous system in primary hypertension.  
Mineral Electrolyte Metab 7:57-66, 1982.

Weder AB:  
Red-cell lithium-sodium countertransport and renal lithium  
clearance in hypertension.  
N Engl J Med 314:198-201, 1986.

Weihe E, Nohr D, Hartschuh W, Gauweiler B, Fink T:  
Multiplicity of opioidergic pathways related to cardiovascular innervation: differential contribution of all three opioid precursors.  
In: Stumpe KO, Kraft K, Faden AI (eds): Opioid peptides and blood pressure control.  
Springer Verlag Berlin pp27-49, 1988.

Weinberger MH, Miller JZ, Luft FC, Fineberg NS, Grim CE,  
Christian JC:  
Genetic aspects of the blood pressure control system.  
Clin Exp Hypertension 3(4):569-581, 1981.

Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS:  
Definitions and characteristics of sodium sensitivity and blood pressure resistance.  
Hypertens 8 [Suppl II]:II-127-II-134, 1986.

Weitz W:  
Zur Ätiologie der genuinen oder vaskulären Hypertension.  
Z klin Medizin 96:151-181, 1923.

Whyte K, Jones CR, Howie CA, Deighton N, Sumner DJ, Reid JL:  
Haemodynamic, metabolic and lymphocyte beta<sub>2</sub>-adrenoceptor changes following chronic beta-adrenoceptor antagonism.  
Eur J Clin Pharmacol 32:237-243, 1987.

Wiemer G, Wellstein A, Palm D, von Hattingberg HM, Brockmeier D:  
Properties of agonist binding at the β-adrenoceptor of the rat reticulocyte.  
Naunyn Schmiedeberg's Arch Pharmacol 321:11-19, 1982.

Williams LT, Snyderman R, Lefkowitz RJ:  
Identification of beta-adrenergic receptors in human lymphocytes by (-)<sup>3</sup>H-alprenolol binding.  
J Clin Invest 57:149-155, 1976.

Williams RR, Hasstedt SJ, Hunt SC, Wu LL, Ash KO:  
Genetic studies of cation tests and hypertension.  
Hypertension 10:37-41, 1987.

Williams RR, Hunt SC, Hasstedt SJ, Berry TD, Wu LL, Barlow GK,  
Stults BM, Kuida H:  
Definition of genetic factors in hypertension: A search for major genes, polygenes, and homogenous subtypes.  
J Cardiovasc Pharmacol 12 [Suppl 3]:7-20, 1988a.

Williams RR, Hunt SC, Hasstedt SJ, Hopkins PN, Wu LL, Stults BM,  
Barlow GK, Kuida H:  
Inherited bimodal traits and susceptibility to hypertension in  
Utah pedigrees.  
Vortrag Berlin 1988b.

Wright GL, Rankin GO:  
Concentration of ionic and total calcium in plasma of four  
models of hypertension.  
Am J Physiol 243:H365-370, 1982.

Yamada S, Yamamura HI, Roeske WR:  
Alterations in central and peripheral adrenergic receptors in  
deoxycorticosterone/salt hypertensive rats.  
Life Sci 27:2405-2416, 1980.

Yamori Y:  
Physiopathology of the various strains of spontaneously  
hypertensive rats. In: Genest J, Kuchel O, Hamet P, Cantin M  
(eds)  
Hypertension McGraw-Hill, Montreal, pp 556-581, 1983)

Yanagisawa M, Kurihara H, Kimura S, Tomabe Y, Kobayashi Y,  
Goto MK, Masaki T:  
A novel potent vasoconstrictor peptide produced by vascular  
endothelial cells.  
Nature (Lond) 332:411-5, 1988.

Yokokawa K, Kohno M, Murakawa K, et al.:  
Acute effects of endothelin on renal hemodynamics and blood  
pressure in anesthetized rats.  
Am J Hypertens 2:715-717, 1989.

Yoshizumi M, Ouchi Y, Souza AC, Sugiyama T, Kurihara H:  
Pressor effect of endothelin in conscious rats.  
Circulation 78 [Suppl II]:II-266, 1988.

Yoshizumi M, Kurihara H, Sugiyama T, et al.:  
Hemodynamic shear stress stimulates endothelin production by  
cultured endothelial cells.  
Biochem Biophys Res Commun 161:859-864, 1989.

van Zwieten PA, Timmermans PBMWM:  
Alpha-adrenoceptor stimulation and calcium movements.  
Blood Vessels 24:271-280, 1987.

van Zwieten PA, Jie K, van Brummelen P:  
Postsynaptic  $\alpha_1$ - and  $\alpha_2$ -adrenoceptor changes in hypertension.  
J Cardiovasc Pharmacol 10 [Suppl 4]:S68-S75, 1987.

